Meet the Company Changing Pain Relief!

Discover a groundbreaking innovation in chronic pain relief that’s redefining the future of non-opioid treatment. In this captivating episode of MedHeads,

Dr. Ferghal Armstrong interviews Samir Sabir, the founder and CEO of Brixton Biosciences, about their revolutionary new product:

Neural Ice.Designed to deliver three to six months of drug-free pain relief with a single injection, Neural Ice is an ultra-long-acting nerve block that uses a completely non-pharmaceutical, cryo-based mechanism to temporarily shut down pain-conducting nerves.

Unlike traditional methods like steroids, radiofrequency ablation (RF), or opioids, this high-tech frozen injection is simple, targeted, and potentially game-changing—especially for patients with chronic knee, hip, or thumb joint pain.

Learn how this Harvard-born technology uses cryolipolysis to induce reversible nerve desensitisation, how it bypasses the risks and complexities of RF, and why it could soon become a standard office-based procedure performed not only by pain doctors but also by orthopaedic surgeons and sports medicine specialists.

If you're looking for non-invasive, long-lasting, and clinician-friendly alternatives to steroids or surgery, this episode is a must-watch. Get the inside scoop on the clinical trials, FDA journey, and the vision for a pain-free future—without the use of opioids.

Chapters00:00 – Welcome and Introduction to Brixton Biosciences

00:45 – What Is Neural Ice and Its Purpose

02:00 – Why Samir Chose to Focus on Chronic Pain

03:30 – How the Nerve Block Works and Its Simplicity

05:00 – The Frozen Injection Mechanism Explained

07:30 – Understanding Cryolipolysis and Myelin Degeneration

10:00 – Neural Ice vs Radiofrequency Ablation (RF)

13:00 – Operator Dependence and Efficacy Compared

15:00 – Applicability for Different Nerve Types

17:00 – Competing with Steroids and HA Injections

19:00 – Injection Site and Clinician Use

21:00 – Ingredients and Engineering of Neural Ice2

4:00 – FDA Trials and Market Timeline

26:00 – Final Thoughts and Patient-Centered Mission